Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase III Study of Palbociclib in Combination With Exemestane or Fulvestrant vs. Chemotherapy (Capecitabine) in Hormonal Receptor Positive/HER2 Negative Metastatic Breast Cancer Patients With Resistance to Aromatase Inhibitors

Next Previous
Trial Profile

Phase III Study of Palbociclib in Combination With Exemestane or Fulvestrant vs. Chemotherapy (Capecitabine) in Hormonal Receptor Positive/HER2 Negative Metastatic Breast Cancer Patients With Resistance to Aromatase Inhibitors

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 27 Sep 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Exemestane (Primary) ; Fulvestrant (Primary) ; Palbociclib (Primary) ; Capecitabine
  • Indications Advanced breast cancer; HER2 negative breast cancer
  • Focus Therapeutic Use
  • Acronyms PEARL

Most Recent Events

  • 09 Dec 2023 Results assessing Body Mass Index and Treatment Efficacy in advanced Luminal Breast Cancer presented at the 46th Annual San Antonio Breast Cancer Symposium
  • 06 Jun 2023 Results investigating the prognostic and predictive value of cytoplasmic and nuclear isoforms of cyclin E in metastatic breast cancer, presented at the 59th Annual Meeting of the American Society of Clinical Oncology
  • 07 Feb 2023 Tumor samples of 455 patients were used for mRNA gene expression profiling and correlation with progression-free-survival (PFS), published in the Clinical Cancer Research

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top